Provexis plc (‘Provexis’ or the ‘Company’), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces its audited preliminary results for the year ended 31 March 2019.
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to provide an update on trading following the end of its financial year on 31 March 2019.
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce the appointment of Dr Niamh O’Kennedy as an Executive Director of the Company, and as Chief Scientific Officer, with immediate effect.
Provexis plc, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces its audited preliminary results for the year ended 31 March 2018.
Provexis plc, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is delighted to announce it has secured a retail listing with Holland & Barrett for the Company’s Fruitflow®+ Omega-3 dietary supplement product.